Evotec SE (LON: 0IRF)

Market Cap	1.20B
Revenue (ttm)	646.62M
Net Income (ttm)	-142.60M
Shares Out	n/a
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,625
Average Volume	54,026
Open	8.02
Previous Close	7.92
Day's Range	7.90 - 8.04
52-Week Range	4.06 - 17.76
Beta	0.98
RSI	42.70
Earnings Date	Apr 11, 2025

About Evotec SE

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exsci...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 5,061
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IRF

Financial Performance

In 2023, Evotec SE's revenue was 781.43 million, an increase of 3.99% compared to the previous year's 751.45 million. Losses were -83.91 million, -52.23% less than in 2022.

Financial numbers in EUR